The emerging differential roles of GABAergic and antiglutamatergic agents in bipolar disorders
1Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Calif 94305, USA. tketter@stanford.edu
Abstract:
Treatment options to relieve the diverse symptoms encountered in patients with bipolar disorders include not only mood stabilizers, but also anxiolytics, new anticonvulsants, antidepressants, and antipsychotics. These agents have widely varying mechanisms of action, which could contribute to the heterogeneity of clinical effects seen in practice. Several of these medications, especially those with anticonvulsant effects, enhance gamma-aminobutyric acid (GABA) inhibitory neurotransmission and/or attenuate glutamate excitatory neurotransmission. We review the efficacy and tolerability of these diverse treatment options in bipolar disorders and explore possible relationships between clinical effects and GABAergic and antiglutamatergic mechanisms of action.
Related Concept Videos
Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Mania and Antimanic Drugs: Overview
Antiepileptic Drugs: Glutamate Antagonists
Bipolar Disorder
Antidepressant Drugs: MAOIs and Other Agents
Ligand-Gated Ion Channel Receptor: Gating Mechanism

